Plain-English translation of NCT06598722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether BCL-2 inhibitors combined with a standard chemotherapy regimen called HyperCVAD can help patients with newly diagnosed T-cell lymphoblastic leukemia or lymphoma (a type of blood cancer) achieve better remission rates. Researchers will compare how well this new combination works compared to previous treatment approaches, looking at how many patients go into remission and how long they stay well.
T-cell lymphoblastic leukemia and lymphoma are aggressive blood cancers that are difficult to treat. This trial aims to see if adding this medication to standard chemotherapy can improve survival and remission rates while remaining safe for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the new medication combination (BCL-2 inhibitors plus HyperCVAD chemotherapy) as your initial treatment for your blood cancer. The study will track how well the treatment works, how long remission lasts, whether the cancer comes back, and what side effects you experience. You would be compared to patients from previous trials who received standard treatment alone, using matching techniques to make the groups as similar as possible.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China